Lan Fen, M.D., Ph.D.

Department:Respiratory Medicine

Medical School:Tongji Medical College, Huazhong University of Science and Technology, China

Academic Rank:Associate Chief Physician


Appointment

Clinical / Research Interests

Individualized and comprehensive treatment of lung cancer; diagnosis of pulmonary nodules; diagnosis and treatment of pulmonary embolism; standardized diagnosis and treatment of chronic airway diseases (eg. bronchial asthma, chronic obstructive pulmonary disease).

Professional Highlights

Advanced Worker of 2013-2015, SAHZU

The Eighth Guangji Academic Week and First Young Teachers' Clinical Skills Competition, First Prize

Professional Appointments

Member, Respiratory Medicine Branch, Zhejiang Medical Association

Member, Lung Cancer Group, Respiratory Medicine Branch, Zhejiang Medical Association

Member, Respiratory Rehabilitation Group, Respiratory Rehabilitation Committee, Chinese Association of Rehabilitation Medicine

Member, Committee of Diagnostic Branch, Clinical Medical Education Research Association, National Association of Higher Medical Education

Guest Editor, Canadian Respiratory Journal

Academic Secretary, Editorial Committee, the 3rd Edition of Asthma Handbook

Education Experience

Research Summary

Immunotherapy and pathogenesis for lung cancer.

Pathogenesis of airway remodeling, especially COPD and asthma.

Publications

Wang, Shaobin, Lan, Fen, Xia, Yang. IncRA ANCR Inhibits Non-Small Cell Lung Cancer Cell Migration and Invasion by Inactivating TGF-β Pathway. Med Sci Monit. 2018 Aug 29; 24:6002-6009.

Xia LX(#), Hua W(#), Jin Y, Tian BP, Qiu ZW, Zhang C, Che LQ, Zhou HB, Wu YF, Huang HQ, Lan F, Ke YH, Lee JJ, Li W, Ying SM, Chen ZH(*), Shen HH(*). Eosinophil differentiation in the bone marrow is promoted by protein tyrosine phosphatase SHP2. Cell Death Dis. 2016 Apr 7;7:e2175. 

Lan F (#), Cao C, Liu J, Li W(*). Obstructive sleep apnea syndrome susceptible genes in the Chinese population: a meta-analysis of 21 case-control studies. Sleep Breath. 2015 Dec;19(4):1441-8. 

Tian BP(#), Hua W, Xia LX, Jin Y, Lan F, Lee JJ, Lee NA, Li W, Ying SM, Chen ZH, Shen HH(*). Exogenous interleukin-17A inhibits eosinophil differentiation and alleviates allergic airway inflammation. Am J Respir Cell Mol Biol. 2015 Apr;52(4):459-70.

Cao C(#), Gu Y, Zhu C, Palmai-Pallag T, Lan F, Chen Z, Li W, Shen H, Ying S(*). Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology. Recent Pat Anticancer Drug Discov. 2014 May;9(2):241-8. 

Li W(#), Lan F, Yan F, Shen H(*). Angiotensin-converting enzyme I/D polymorphism is associated with COPD risk in Asian population: evidence from a Meta-analysis. COPD. 2013 Feb;10(1):35-9.

Hu Q(#), Zuo P, Shao B, Yang S, Xu G, Lan F, Lu X, Xiong W, Xu Y, Xiong S(*). Administration of nonviral gene vector encoding rat beta-defensin-2 ameliorates chronic Pseudomonas aeruginosa lung infection in rats. J Gene Med. 2010 Mar;12(3):276-86.

Lan F(#), Tong Y, Huang H, Xiong W, Xu Y,Xiong S(*). Primary Pulmonary Coccidioidomycosis in China: A Case Report. Respirology.2010, 15(4):722-5.

Hu WK(#), Lu XX, Yang S, Xu GP, Lan F, Chen SX, Ni W, Xiong WN, Xiong SD(*). Expression of the Th1-specific cell-surface protein Tim-3 increases in a murine model of atopic asthma. J Asthma. 2009 Nov;46(9):872-7.

Lan F(#), Shengdao XIONG(*), Weining XIONG, GuopengXu, Xiaoxia Lu. The Expression of Syk in Non-Small Cell Lung Cancer and its Relationship with Clinicopathological Parameters. Frontiers of Medicine in China, 2009, 1(3):41-44.



Current Program

The study of PHD2 in the airway remodeling of chronic asthma. Funding Source: National Natural Science Foundation of China (81000010).

Regulation and mechanism of PHD2-HIF-1αsignaling pathway in the differentiation of eosinophils in bone marrow of asthma. Funding Source: Natural Science Foundation of Zhejiang (LY15H010002).

A randomized, national multicenter study comparing Pembrolizumab every 3 weeks with maintenance every 6 weeks in patients with advanced non-small cell lung cancer (NSCLC) treated first line with PD-L1≥1%. Funding Source: The Second Affiliated Hospital Zhejiang University School of Medicine.

Find People

Search by Family Name

Find A Department

Search by Departments